FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377016745> ?p ?o ?g. }

• W4377016745 endingPage "101995" @default.
• W4377016745 startingPage "101995" @default.
• W4377016745 abstract "BackgroundHeavy menstrual bleeding affects one in four women and negatively impacts quality of life. Ulipristal acetate is prescribed to treat symptoms associated with uterine fibroids. We compared the effectiveness of ulipristal acetate and the levonorgestrel-releasing intrauterine system at reducing the burden of heavy menstrual bleeding, irrespective of the presence of fibroids.MethodsThis randomised, open-label, parallel group phase III trial enrolled women over 18 years with heavy menstrual bleeding from 10 UK hospitals. Participants were centrally randomised, in a 1:1 ratio, to either three, 12-week treatment cycles of 5 mg ulipristal acetate daily, separated by 4-week treatment-free intervals, or a levonorgestrel-releasing intrauterine system. The primary outcome, analysed by intention-to-treat, was quality of life measured by the Menorrhagia Multi-Attribute Scale at 12 months. Secondary outcomes included menstrual bleeding and liver function. The trial is registered with ISRCTN, 20426843.FindingsBetween June 5th, 2015 and February 26th, 2020, 236 women were randomised, either side of a recruitment suspension due to concerns of ulipristal acetate hepatoxicity. Subsequent withdrawal of ulipristal acetate led to early cessation of recruitment but the trial continued in follow-up. The primary outcome substantially improved in both groups, and was 89, (interquartile range [IQR] 65 to 100, n = 53) and 94, (IQR 70 to 100, n = 50; adjusted odds ratio 0.55, 95% confidence interval [CI] 0.26–1.17; p = 0.12) in the ulipristal and levonorgestrel-releasing intrauterine system groups. Rates of amenorrhoea at 12 months were higher in those allocated ulipristal acetate compared to levonorgestrel-releasing intrauterine system (64% versus 25%, adjusted odds ratio 7.12, 95% CI 2.29–22.2). Other outcomes were similar between the two groups and there were no cases of endometrial malignancy or hepatotoxicity due to ulipristal acetate use.InterpretationOur findings suggested that both treatments improved quality of life. Ulipristal was more effective at inducing amenorrhoea. Ulipristal has been demonstrated to be an effective medical therapeutic option but currently its use has restrictions and requires liver function monitoring.FundingUK Medical Research Council and National Institute of Health Research EME Programme (12/206/52). Heavy menstrual bleeding affects one in four women and negatively impacts quality of life. Ulipristal acetate is prescribed to treat symptoms associated with uterine fibroids. We compared the effectiveness of ulipristal acetate and the levonorgestrel-releasing intrauterine system at reducing the burden of heavy menstrual bleeding, irrespective of the presence of fibroids. This randomised, open-label, parallel group phase III trial enrolled women over 18 years with heavy menstrual bleeding from 10 UK hospitals. Participants were centrally randomised, in a 1:1 ratio, to either three, 12-week treatment cycles of 5 mg ulipristal acetate daily, separated by 4-week treatment-free intervals, or a levonorgestrel-releasing intrauterine system. The primary outcome, analysed by intention-to-treat, was quality of life measured by the Menorrhagia Multi-Attribute Scale at 12 months. Secondary outcomes included menstrual bleeding and liver function. The trial is registered with ISRCTN, 20426843. Between June 5th, 2015 and February 26th, 2020, 236 women were randomised, either side of a recruitment suspension due to concerns of ulipristal acetate hepatoxicity. Subsequent withdrawal of ulipristal acetate led to early cessation of recruitment but the trial continued in follow-up. The primary outcome substantially improved in both groups, and was 89, (interquartile range [IQR] 65 to 100, n = 53) and 94, (IQR 70 to 100, n = 50; adjusted odds ratio 0.55, 95% confidence interval [CI] 0.26–1.17; p = 0.12) in the ulipristal and levonorgestrel-releasing intrauterine system groups. Rates of amenorrhoea at 12 months were higher in those allocated ulipristal acetate compared to levonorgestrel-releasing intrauterine system (64% versus 25%, adjusted odds ratio 7.12, 95% CI 2.29–22.2). Other outcomes were similar between the two groups and there were no cases of endometrial malignancy or hepatotoxicity due to ulipristal acetate use. Our findings suggested that both treatments improved quality of life. Ulipristal was more effective at inducing amenorrhoea. Ulipristal has been demonstrated to be an effective medical therapeutic option but currently its use has restrictions and requires liver function monitoring." @default.
• W4377016745 created "2023-05-19" @default.
• W4377016745 creator A5000333627 @default.
• W4377016745 creator A5000758879 @default.
• W4377016745 creator A5001175772 @default.
• W4377016745 creator A5006184660 @default.
• W4377016745 creator A5009972599 @default.
• W4377016745 creator A5019395613 @default.
• W4377016745 creator A5023637812 @default.
• W4377016745 creator A5030930708 @default.
• W4377016745 creator A5039171576 @default.
• W4377016745 creator A5045595046 @default.
• W4377016745 creator A5045905418 @default.
• W4377016745 creator A5056062193 @default.
• W4377016745 creator A5056323976 @default.
• W4377016745 creator A5060414786 @default.
• W4377016745 creator A5074793818 @default.
• W4377016745 creator A5075247482 @default.
• W4377016745 creator A5085303209 @default.
• W4377016745 creator A5085774957 @default.
• W4377016745 creator A5087241179 @default.
• W4377016745 creator A5090884853 @default.
• W4377016745 date "2023-06-01" @default.
• W4377016745 modified "2023-09-29" @default.
• W4377016745 title "Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding (UCON): a randomised controlled phase III trial" @default.
• W4377016745 cites W1853819257 @default.
• W4377016745 cites W1932709689 @default.
• W4377016745 cites W1977733462 @default.
• W4377016745 cites W1990166011 @default.
• W4377016745 cites W1996284739 @default.
• W4377016745 cites W2035950836 @default.
• W4377016745 cites W2042374015 @default.
• W4377016745 cites W2062244353 @default.
• W4377016745 cites W2106587450 @default.
• W4377016745 cites W2107942005 @default.
• W4377016745 cites W2149860264 @default.
• W4377016745 cites W2152498789 @default.
• W4377016745 cites W2156957181 @default.
• W4377016745 cites W2531637721 @default.
• W4377016745 cites W2891991898 @default.
• W4377016745 cites W2899820374 @default.
• W4377016745 cites W2921506721 @default.
• W4377016745 cites W2972653961 @default.
• W4377016745 cites W3002354512 @default.
• W4377016745 cites W3047551484 @default.
• W4377016745 cites W3113899924 @default.
• W4377016745 cites W4210871755 @default.
• W4377016745 cites W4214564201 @default.
• W4377016745 cites W4307869271 @default.
• W4377016745 doi "https://doi.org/10.1016/j.eclinm.2023.101995" @default.
• W4377016745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37251622" @default.
• W4377016745 hasPublicationYear "2023" @default.
• W4377016745 type Work @default.
• W4377016745 citedByCount "1" @default.
• W4377016745 countsByYear W43770167452023 @default.
• W4377016745 crossrefType "journal-article" @default.
• W4377016745 hasAuthorship W4377016745A5000333627 @default.
• W4377016745 hasAuthorship W4377016745A5000758879 @default.
• W4377016745 hasAuthorship W4377016745A5001175772 @default.
• W4377016745 hasAuthorship W4377016745A5006184660 @default.
• W4377016745 hasAuthorship W4377016745A5009972599 @default.
• W4377016745 hasAuthorship W4377016745A5019395613 @default.
• W4377016745 hasAuthorship W4377016745A5023637812 @default.
• W4377016745 hasAuthorship W4377016745A5030930708 @default.
• W4377016745 hasAuthorship W4377016745A5039171576 @default.
• W4377016745 hasAuthorship W4377016745A5045595046 @default.
• W4377016745 hasAuthorship W4377016745A5045905418 @default.
• W4377016745 hasAuthorship W4377016745A5056062193 @default.
• W4377016745 hasAuthorship W4377016745A5056323976 @default.
• W4377016745 hasAuthorship W4377016745A5060414786 @default.
• W4377016745 hasAuthorship W4377016745A5074793818 @default.
• W4377016745 hasAuthorship W4377016745A5075247482 @default.
• W4377016745 hasAuthorship W4377016745A5085303209 @default.
• W4377016745 hasAuthorship W4377016745A5085774957 @default.
• W4377016745 hasAuthorship W4377016745A5087241179 @default.
• W4377016745 hasAuthorship W4377016745A5090884853 @default.
• W4377016745 hasBestOaLocation W43770167451 @default.
• W4377016745 hasConcept C119060515 @default.
• W4377016745 hasConcept C126322002 @default.
• W4377016745 hasConcept C131872663 @default.
• W4377016745 hasConcept C156957248 @default.
• W4377016745 hasConcept C168563851 @default.
• W4377016745 hasConcept C2776810592 @default.
• W4377016745 hasConcept C2777486506 @default.
• W4377016745 hasConcept C2779076696 @default.
• W4377016745 hasConcept C2780186607 @default.
• W4377016745 hasConcept C2780566971 @default.
• W4377016745 hasConcept C2908647359 @default.
• W4377016745 hasConcept C29456083 @default.
• W4377016745 hasConcept C2986817661 @default.
• W4377016745 hasConcept C2992922752 @default.
• W4377016745 hasConcept C71924100 @default.
• W4377016745 hasConcept C99454951 @default.
• W4377016745 hasConceptScore W4377016745C119060515 @default.
• W4377016745 hasConceptScore W4377016745C126322002 @default.
• W4377016745 hasConceptScore W4377016745C131872663 @default.
• W4377016745 hasConceptScore W4377016745C156957248 @default.
• W4377016745 hasConceptScore W4377016745C168563851 @default.

• next